公开(公告)号：US08623607B2

公开(公告)日：2014-01-07

申请号：US13280719

申请日：2011-10-25

申请人： Florian Kronenberg ,  Barbara Kollerits ,  Danilo Fliser

发明人： Florian Kronenberg ,  Barbara Kollerits ,  Danilo Fliser

IPC分类号： G01N33/53

CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/118

摘要： The present invention relates to a method for determining or predicting the progression of chronic kidney disease in a subject suspected of having chronic kidney disease, comprising determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.

摘要翻译： 本发明涉及一种用于确定或预测疑似患有慢性肾脏疾病的受试者的慢性肾脏疾病进展的方法，包括确定选自（a）FGF23的至少一种标志物的表达水平; 和（b）生物样品中的脂联素。 此外，本发明涉及用于FGF23或脂联素的特异性检测分子用于制备用于检测疑似患有所述疾病的受试者的慢性肾脏疾病或慢性肾脏疾病进展的诊断组合物的用途。 特别地，本发明还提供使用FGF23和/或脂连蛋白作为慢性肾脏疾病的存在，不存在或进展的体外标记物，以及包含用于FGF23的特异性检测分子或脂联素特异性检测分子的试剂盒 用于本发明的方法中。

公开(公告)号：US20100143951A1

公开(公告)日：2010-06-10

申请号：US12523625

申请日：2008-01-21

申请人： Florian Kronenberg ,  Barbara Kollerits ,  Danilo Fliser

发明人： Florian Kronenberg ,  Barbara Kollerits ,  Danilo Fliser

IPC分类号： G01N33/53

CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/118

摘要： The present invention relates to a method for the determination or prediction of the progression of chronic kidney disease in a subject suspected to suffer from chronic kidney disease, said method comprising the step of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or use of a specific detection molecule for adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.

摘要翻译： 本发明涉及一种用于确定或预测疑似患有慢性肾脏疾病的受试者的慢性肾脏疾病进展的方法，所述方法包括确定选自（a）的至少一种标志物的表达水平的步骤， FGF23; 和（b）生物样品中的脂联素。 此外，本发明涉及用于FGF23的特异性检测分子的用途或者用于脂联素的特异性检测分子的用途，用于制备用于检测受试者的慢性肾脏疾病或慢性肾脏疾病进展的诊断组合物 患有所述疾病。 特别地，本发明还提供使用FGF23和/或脂连蛋白作为慢性肾脏疾病的存在，不存在或进展的体外标记物，以及包含用于FGF23的特异性检测分子或脂联素特异性检测分子的试剂盒 用于本发明的方法中。

公开(公告)号：US20120135428A1

公开(公告)日：2012-05-31

申请号：US13280719

申请日：2011-10-25

申请人： Florian Kronenberg ,  Barbara Kollerits ,  Danilo Fliser

发明人： Florian Kronenberg ,  Barbara Kollerits ,  Danilo Fliser

IPC分类号： G01N33/566 ,  C07K16/22 ,  C07K16/26

CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/118

摘要： The present invention relates to a method for determining the progression of chronic kidney disease in a subject suspected of having chronic kidney disease, comprising of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.

摘要翻译： 本发明涉及一种用于确定疑似患有慢性肾脏疾病的受试者的慢性肾脏疾病进展的方法，包括确定选自（a）FGF23的至少一种标志物的表达水平; 和（b）生物样品中的脂联素。 此外，本发明涉及用于FGF23或脂联素的特异性检测分子用于制备用于检测疑似患有所述疾病的受试者的慢性肾脏疾病或慢性肾脏疾病进展的诊断组合物的用途。 特别地，本发明还提供使用FGF23和/或脂连蛋白作为慢性肾脏疾病的存在，不存在或进展的体外标记物，以及包含用于FGF23的特异性检测分子或脂联素特异性检测分子的试剂盒 用于本发明的方法中。

公开(公告)号：US08058015B2

公开(公告)日：2011-11-15

申请号：US12523625

申请日：2008-01-21

申请人： Florian Kronenberg ,  Barbara Kollerits ,  Danilo Fliser

发明人： Florian Kronenberg ,  Barbara Kollerits ,  Danilo Fliser

IPC分类号： G01N33/53

CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/118

摘要： The present invention relates to a method for the determination or prediction of the progression of chronic kidney disease in a subject suspected to suffer from chronic kidney disease, said method comprising the step of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or use of a specific detection molecule for adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.

摘要翻译： 本发明涉及一种用于确定或预测疑似患有慢性肾脏疾病的受试者的慢性肾脏疾病进展的方法，所述方法包括确定选自（a）的至少一种标志物的表达水平的步骤， FGF23; 和（b）生物样品中的脂联素。 此外，本发明涉及用于FGF23的特异性检测分子的用途或者用于脂联素的特异性检测分子的用途，用于制备用于检测受试者的慢性肾脏疾病或慢性肾脏疾病进展的诊断组合物 患有所述疾病。 特别地，本发明还提供使用FGF23和/或脂连蛋白作为慢性肾脏疾病的存在，不存在或进展的体外标记物，以及包含用于FGF23的特异性检测分子或脂联素特异性检测分子的试剂盒 用于本发明的方法中。

公开(公告)号：US20130122523A1

公开(公告)日：2013-05-16

申请号：US13635348

申请日：2011-03-21

申请人： Ferdinand Hermann Bahlmann ,  Danilo Fliser ,  Martina Sester ,  Urban Sester

发明人： Ferdinand Hermann Bahlmann ,  Danilo Fliser ,  Martina Sester ,  Urban Sester

IPC分类号： G01N33/68

CPC分类号： G01N33/5695 ,  G01N33/6863 ,  G01N33/6866 ,  G01N33/6869 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2800/56

摘要： An in-vitro process for the quick determination of the infection status of a Mycobacterium tuberculosis infection from whole blood in terms of active or latent tuberculosis, comprising the steps of: stimulating an antigen-specific T cell that is present in a first sample of whole blood with purified protein derivative (PPD) in the presence of antibodies against CD28, or CD28 and CD49d; processing of PPD by antigen-presenting cells (APC) by incubating for 1.5 h to 2.5 h, especially for 2 h, at 35° C. to 39° C., especially at 37° C., optionally with adding CO2; then adding a secretion inhibitor; effecting an intensive mixing; and another incubation for a period of at least 2.5 h at a temperature of from 35° C. to 39° C., and determining a cytokine profile from both the intracellular INF-γ production and the intracellular IL-2 production of the antigen-specific T cell; wherein the presence of an active tuberculosis is indicated by a shift of the cytokine profile towards IFN-γ single positive cells accompanied by a decrease of IFN-γ/IL-2 double positive T cells.

摘要翻译： 一种在活性或潜伏性结核病方面快速测定全血结核分枝杆菌感染感染状态的体外方法，包括以下步骤：刺激存在于全部第一样品中的抗原特异性T细胞 在存在针对CD28或CD28和CD49d的抗体的情况下，用纯化蛋白质衍生物（PPD） 通过在35℃至39℃，特别是37℃，任选加入CO 2的温度下孵育1.5小时至2.5小时，特别是2小时，通过抗原呈递细胞（APC）处理PPD; 然后加入分泌抑制剂; 进行密集混合; 并且在35℃至39℃的温度下另外孵育至少2.5小时的时间，并且从细胞内INF-γ产生和抗原决定簇的细胞内IL-2产生中确定细胞因子谱， 特异性T细胞; 其中活动性结核病的存在通过伴随IFN-γ/ IL-2双重阳性T细胞减少的IFN-γ单个阳性细胞的细胞因子分布的移位来表示。